RxDoctor Payments Data

Shakira Sanders, APRN

Family · Paducah, KYNPI 1922550300

Payments from drug & device makers

$6,234in general payments, 2019–2025

Across 339 payments — averaging $18.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$1K
  • Merck$633
  • E.r. Squibb & Sons, L.L.C.$567
  • AstraZeneca$439
  • Pfizer$422
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$382
  • plus $2K from 26 others

What the payments were for

  • Grants$250%
  • Food & beverage$6,09498%
  • Education$1152%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,234 in reported general payments places this provider in the 90th percentile of 4,374 family providers in Kentucky.

See all family providers in Kentucky

Medicare billing

Part B allowed, 2024
$65,166
Medicare patients
368
Services billed
896

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan373$328,074
EliquisApixaban266$263,371
JardianceEmpagliflozin125$120,048
FarxigaDapagliflozin Propanediol123$100,379
XareltoRivaroxaban82$59,339
BrilintaTicagrelor32$23,028
MultaqDronedarone Hcl21$22,075
Repatha SureclickEvolocumab23$14,632
Ranolazine ErRanolazine101$10,768
Spironolactone408$3,254
Metoprolol Succinate238$2,945
Clonidine20$2,890
Diltiazem 24hr Er (Cd)Diltiazem Hcl46$2,165
Losartan Potassium212$1,697
Midodrine Hcl20$1,446

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$1,302$328,074373 claims
PfizerEliquis$422$263,371266 claims
AstraZenecaFarxiga, Brilinta$439$123,406155 claims
Boehringer IngelheimJardiance$298$120,048125 claims
Johnson & JohnsonXarelto$223$59,33982 claims
Sanofi-aventis U.S. LLCMultaq$156$22,07521 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,374 family providers in Kentucky.

Other family in Paducah

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →